Patient groups and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, and the Interim Plasma Protein Product Review).
To help patient groups and patients contribute to the consultation, this webinar will highlight proposed changes that impact patient groups. Comments shared by patient groups and patients during the webinar will be included as stakeholder feedback.
See Summary of Proposed Procedures for CADTH Drug Reimbursement Reviews for more details on the consultation.
- Sarah Berglas, Manager, Patient Engagement, CADTH
- Trevor Richter, Director, Pharmaceutical Reviews, CADTH
- Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH